HRP20231631T1 - Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci - Google Patents
Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci Download PDFInfo
- Publication number
- HRP20231631T1 HRP20231631T1 HRP20231631TT HRP20231631T HRP20231631T1 HR P20231631 T1 HRP20231631 T1 HR P20231631T1 HR P20231631T T HRP20231631T T HR P20231631TT HR P20231631 T HRP20231631 T HR P20231631T HR P20231631 T1 HRP20231631 T1 HR P20231631T1
- Authority
- HR
- Croatia
- Prior art keywords
- clostridium difficile
- cell
- progeny
- recombinant cell
- bacterium
- Prior art date
Links
- 241000193163 Clostridioides difficile Species 0.000 title claims 19
- 238000000034 method Methods 0.000 title claims 11
- 239000003053 toxin Substances 0.000 title claims 2
- 231100000765 toxin Toxicity 0.000 title claims 2
- 239000000203 mixture Substances 0.000 title 1
- 101710084578 Short neurotoxin 1 Proteins 0.000 claims 8
- 101710182532 Toxin a Proteins 0.000 claims 8
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 230000028070 sporulation Effects 0.000 claims 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims 1
- 241000192125 Firmicutes Species 0.000 claims 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 101150042065 spo0A gene Proteins 0.000 claims 1
- 108700012359 toxins Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (19)
1. Rekombinantna stanica ili njezino potomstvo, naznačena time što sadrži nukleinskokiselinski slijed koji kodira mutantni toksin A iz bakterije Clostridium difficile sa SEQ ID NO: 4, SEQ ID NO: 7 ili SEQ ID NO: 83.
2. Rekombinantna stanica, ili njezino potomstvo, u skladu s patentnim zahtjevom 1, naznačena time što sadrži SEQ ID NO: 12 ili SEQ ID NO: 45.
3. Rekombinantna stanica, ili njezino potomstvo, u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se navedenu stanicu dobiva iz stanice Gram-pozitivne bakterije.
4. Rekombinantna stanica, ili njezino potomstvo, u skladu s patentnim zahtjevom 1, 2 ili 3, naznačena time što se stanicu dobiva iz stanice bakterije Clostridium difficile.
5. Rekombinantna stanica, ili njezino potomstvo, u skladu s bilo kojim od patentnih zahtjeva 1-4, naznačena time što stanica ne sadrži endogeni polinukleotid koji kodira toksin.
6. Rekombinantna stanica, ili njezino potomstvo, u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačena time što se stanicu dobiva iz stanice bakterije Clostridium difficile bira iz skupine koju čine Clostridium difficile 1351, Clostridium difficile 3232, Clostridium difficile 7322, Clostridium difficile 5036, Clostridium difficile 4811, te Clostridium difficile VPI 11186.
7. Rekombinantna stanica, ili njezino potomstvo, u skladu s patentnim zahtjevom 6, naznačena time što je stanica stanica bakterije Clostridium difficile VPI 11186.
8. Rekombinantna stanica, ili njezino potomstvo, u skladu s patentnim zahtjevom 4, 6 ili 7, naznačena time što je sporulacijski gen iz stanice bakterije Clostridium difficile inaktiviran.
9. Rekombinantna stanica, ili njezino potomstvo, u skladu s patentnim zahtjevom 8, naznačena time što sporulacijski gen uključuje gen spo0A ili gen spollE.
10. Postupak proizvodnje mutantnog toksina A iz bakterije Clostridium difficile, naznačen time što se sastoji u uzgoju rekombinantne stanice, ili njezinog potomstva, u skladu s bilo kojim od patentnih zahtjeva 1-9, u uvjetima pogodnim za eksprimiranje polinukleotida koji kodira mutantni toksin A iz bakterije Clostridium difficile.
11. Postupak u skladu s patentnim zahtjevom 10, naznačen time što dodatno uključuje izoliranje mutantnog toksina A iz bakterije Clostridium difficile.
12. Postupak u skladu s patentnim zahtjevom 11, naznačen time što dodatno uključuje stavljanje u kontakt izoliranog mutantnog toksina A iz bakterije Clostridium difficile s formaldehidom.
13. Postupak u skladu s patentnim zahtjevom 12, naznačen time što se stavljanje u kontakt provodi u trajanju od najviše 14 dana ili najviše 48 sati.
14. Postupak u skladu s patentnim zahtjevom 13, naznačen time što se stavljanje u kontakt provodi na otprilike 25 °C.
15. Postupak u skladu s patentnim zahtjevom 11, naznačen time što dodatno uključuje stavljanje u kontakt izoliranog mutantnog toksina A iz bakterije Clostridium difficile s etil-3-(3-dimetilaminopropil)karbodiimidom.
16. Postupak u skladu s patentnim zahtjevom 15, naznačen time što se stavljanje u kontakt provodi u trajanju od najviše 24 sata ili u trajanju od najviše 4 sata.
17. Postupak u skladu s patentnim zahtjevom 15, naznačen time što se stavljanje u kontakt provodi na otprilike 25 °C.
18. Postupak u skladu s patentnim zahtjevom 15, naznačen time što dodatno uključuje stavljanje u kontakt izoliranog mutantnog toksina A iz bakterije Clostridium difficile s N-hidroksisukcinimidom.
19. Imunogeni pripravak, naznačen time što sadrži mutantni toksin A iz bakterije C. difficile, kojeg se proizvodi postupkom u skladu s bilo kojim od patentnih zahtjeva 10 do 18.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161478474P | 2011-04-22 | 2011-04-22 | |
US201161478899P | 2011-04-25 | 2011-04-25 | |
EP19151036.1A EP3505531B1 (en) | 2011-04-22 | 2012-04-20 | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231631T1 true HRP20231631T1 (hr) | 2024-03-15 |
Family
ID=46085103
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231631TT HRP20231631T1 (hr) | 2011-04-22 | 2012-04-20 | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci |
HRP20240042TT HRP20240042T1 (hr) | 2011-04-22 | 2012-04-20 | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20240042TT HRP20240042T1 (hr) | 2011-04-22 | 2012-04-20 | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci |
Country Status (29)
Country | Link |
---|---|
US (13) | US8481692B2 (hr) |
EP (4) | EP3549949B1 (hr) |
JP (8) | JP5917682B2 (hr) |
KR (1) | KR101667837B1 (hr) |
CN (3) | CN111647059B (hr) |
AR (1) | AR086199A1 (hr) |
AU (6) | AU2012245904B2 (hr) |
BR (2) | BR122019017005B1 (hr) |
CA (1) | CA2832712C (hr) |
CO (1) | CO6801643A2 (hr) |
DK (2) | DK3549949T3 (hr) |
ES (3) | ES2742823T3 (hr) |
FI (1) | FI3549949T3 (hr) |
HR (2) | HRP20231631T1 (hr) |
HU (1) | HUE047085T2 (hr) |
IL (8) | IL270779B1 (hr) |
MX (1) | MX347521B (hr) |
MY (2) | MY168205A (hr) |
NZ (1) | NZ616035A (hr) |
PE (2) | PE20181334A1 (hr) |
PL (3) | PL2699587T3 (hr) |
PT (2) | PT3549949T (hr) |
RU (2) | RU2592686C2 (hr) |
SA (3) | SA115360698B1 (hr) |
SG (3) | SG10201602668VA (hr) |
SI (3) | SI3505531T1 (hr) |
TW (6) | TWI701257B (hr) |
WO (1) | WO2012143902A1 (hr) |
ZA (1) | ZA201307818B (hr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2054044B1 (de) * | 2006-08-02 | 2014-07-23 | Johannes Gutenberg-Universität Mainz | Arzneimittel gegen lct-vergiftungen |
MY160201A (en) * | 2008-12-09 | 2017-02-28 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
US9598472B2 (en) | 2010-09-03 | 2017-03-21 | Valneva Austria Gmbh | Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof |
SG10201602668VA (en) | 2011-04-22 | 2016-05-30 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
EP2888283B1 (en) | 2012-08-24 | 2018-09-19 | The Regents of The University of California | Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis |
US20140081659A1 (en) | 2012-09-17 | 2014-03-20 | Depuy Orthopaedics, Inc. | Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking |
BR122016023101B1 (pt) * | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
TWI615158B (zh) * | 2012-11-06 | 2018-02-21 | 拜耳製藥股份有限公司 | 多肽之調配物 |
US9493518B2 (en) * | 2013-03-14 | 2016-11-15 | National Health Research Institutes | Compositions and methods for treating clostridium difficile-associated diseases |
EP2968508B1 (en) | 2013-03-15 | 2022-04-27 | Sanofi Pasteur Biologics, LLC | Antibodies against clostridium difficile toxins and methods of using the same |
AU2014257172B2 (en) * | 2013-04-22 | 2019-01-31 | Board Of Regents Of The University Of Oklahoma | Clostridium difficile vaccine and methods of use |
AU2014277981B2 (en) | 2013-06-14 | 2019-06-20 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against C. difficile |
US9717711B2 (en) | 2014-06-16 | 2017-08-01 | The Lauridsen Group | Methods and compositions for treating Clostridium difficile associated disease |
WO2016012587A1 (en) * | 2014-07-25 | 2016-01-28 | Biosynth S.R.L. | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria |
US11434264B2 (en) * | 2015-02-13 | 2022-09-06 | Quanterix Corporation | Immunoassays for differential detection of clostridium difficile |
US11185555B2 (en) | 2016-04-11 | 2021-11-30 | Noah James Harrison | Method to kill pathogenic microbes in a patient |
US10688181B2 (en) | 2016-06-27 | 2020-06-23 | The Regents Of The University Of California | Cancer treatment combinations |
US20190211377A1 (en) * | 2016-12-22 | 2019-07-11 | Roche Molecular Systems, Inc. | Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile |
BR112020005631A2 (pt) * | 2017-09-28 | 2020-12-29 | Pfizer Inc. | Composições e métodos para eliciar uma resposta imune contra o clostridium difficile |
WO2020201985A1 (en) | 2019-04-01 | 2020-10-08 | Pfizer Inc. | Compositions and methods for eliciting an immune response against clostridium difficile |
US20220313809A1 (en) * | 2019-05-10 | 2022-10-06 | The Board Of Regents Of The University Of Oklahoma | Clostridioides difficile tcdb variants, vaccines and methods of use |
WO2020231930A1 (en) * | 2019-05-11 | 2020-11-19 | The Texas A&M University System | Protein inhibitors of clostridium difficile toxin b |
KR102376876B1 (ko) | 2020-04-09 | 2022-03-21 | 대진대학교 산학협력단 | 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도 |
WO2021226330A1 (en) * | 2020-05-06 | 2021-11-11 | Albert Einstein College Of Medicine | Agents to prevent tissue damage from clostridium difficile infections by inhibition of the gut-damaging bacterial toxins tcda and tcdb |
CN111755068B (zh) * | 2020-06-19 | 2021-02-19 | 深圳吉因加医学检验实验室 | 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置 |
EP4168032A2 (en) | 2020-06-19 | 2023-04-26 | Pfizer Inc. | Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof |
WO2023175454A1 (en) | 2022-03-14 | 2023-09-21 | Pfizer Inc. | Methods for producing an adjuvant |
WO2023232901A1 (en) | 2022-06-01 | 2023-12-07 | Valneva Austria Gmbh | Clostridium difficile vaccine |
US20240189410A1 (en) | 2022-12-13 | 2024-06-13 | Pfizer Inc. | Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS58216123A (ja) | 1982-06-10 | 1983-12-15 | Kazue Ueno | 抗血清 |
US4689299A (en) | 1982-09-30 | 1987-08-25 | University Of Rochester | Human monoclonal antibodies against bacterial toxins |
US4713240A (en) | 1985-04-04 | 1987-12-15 | Research Corporation | Vaccines based on insoluble supports |
US5358868A (en) | 1987-11-24 | 1994-10-25 | Connaught Laboratories Limited | Genetic detoxification of pertussis toxin |
US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5599539A (en) | 1989-10-31 | 1997-02-04 | Ophidian Pharmaceuticals, Inc. | Therapy for clostridial botulinum toxin |
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US5601823A (en) | 1989-10-31 | 1997-02-11 | Ophidian Pharmaceuticals, Inc. | Avian antitoxins to clostridium difficle toxin A |
US5578308A (en) | 1990-02-12 | 1996-11-26 | Capiau; Carine | Glutaraldehyde and formalin detoxified bordetella toxin vaccine |
US5231003A (en) | 1990-05-11 | 1993-07-27 | Cambridge Bioscience Corporation | Monoclonal antibodies specific for toxin b of clostridium difficile |
ATE161967T1 (de) | 1991-04-22 | 1998-01-15 | Massachusetts Health Res | Verfahren für das screening von plasma-proben für einen effektiven antikörpernachweis gegen respiratorische viren |
US6221363B1 (en) | 1991-07-11 | 2001-04-24 | Baxter Aktiengesellschaft | Vaccine for the prevention of lyme disease |
EP0692974B2 (en) | 1993-03-29 | 2007-05-30 | Pfizer Inc. | Multicomponent clostridial vaccines using saponin adjuvants |
MX9701683A (es) | 1994-09-06 | 1997-06-28 | Galagen Inc | Tratamiento terapeutico de enfermedades asociadas a clostridium difficile. |
BR9509903A (pt) | 1994-10-24 | 1997-11-25 | Ophidian Pharm Inc | Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial |
US6743430B1 (en) | 1995-03-29 | 2004-06-01 | Richard E. Parizek | Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose |
US5610023A (en) | 1995-03-31 | 1997-03-11 | Lee Laboratories, Inc. | Method of purification of clostridium difficile toxin A and production of mono-specific antibodies |
DE69610106D1 (de) | 1995-07-07 | 2000-10-05 | Oravax Inc | Toxine und toxoide von clostridium difficile als schleimhautadjuvans |
JPH11510793A (ja) | 1995-07-07 | 1999-09-21 | オラバックス インク. | 胃腸病に対する鼻腔内ワクチン接種 |
US5919463A (en) | 1995-07-07 | 1999-07-06 | Oravax, Inc. | Clostridium difficle toxins as mucosal adjuvants |
WO1997009886A1 (en) | 1995-09-15 | 1997-03-20 | Gerding Dale N | Methods and compositions for prevention and treatment of clostridium difficile-associated diseases |
JP4224136B2 (ja) | 1996-07-12 | 2009-02-12 | ファースト オピニオン コーポレーション | リストベース処理を用いたコンピュータ化医療診断システム |
CA2264810C (en) | 1996-09-30 | 2010-07-27 | Embrex, Inc. | Method of producing active immunity with vaccine conjugate |
US20100267012A1 (en) | 1997-11-04 | 2010-10-21 | Bergeron Michel G | Highly conserved genes and their use to generate probes and primers for detection of microorganisms |
DK1005368T3 (da) | 1997-03-10 | 2010-01-04 | Ottawa Hospital Res Inst | Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer |
US6299881B1 (en) | 1997-03-24 | 2001-10-09 | Henry M. Jackson Foundation For The Advancement Of Military Medicine | Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts |
US20050106157A1 (en) | 1997-05-27 | 2005-05-19 | Deckers Harm M. | Immunogenic formulations comprising oil bodies |
WO1998059053A1 (en) | 1997-06-20 | 1998-12-30 | Queen Mary & Westfield College | Immonogenic fragments of toxin a of clostridium difficile |
DE19739685A1 (de) | 1997-09-10 | 1999-03-11 | Eichel Streiber Christoph Von | Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile |
EP1568378B1 (en) | 1997-10-20 | 2016-03-16 | Sanofi Pasteur Biologics, LLC | Immunization against Clostridium difficile disease |
DE69829400T2 (de) | 1997-10-20 | 2006-04-13 | Acambis, Inc., Cambridge | Passive immunisierung gegen durch clostridium difficile verursachte krankheit |
US6969520B2 (en) | 1997-10-20 | 2005-11-29 | Acambis Inc. | Active immunization against clostridium difficile disease |
US6733760B1 (en) | 1999-04-09 | 2004-05-11 | Techlab, Inc. | Recombinant toxin A/toxin B vaccine against Clostridium difficile |
WO2000061761A2 (en) | 1999-04-09 | 2000-10-19 | Techlab, Inc. | Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines |
EP2502998A3 (en) | 1999-04-09 | 2013-02-27 | Intercell USA, Inc. | Recombinant toxin A/ToxinB vaccine against clostridium difficile |
WO2000062800A2 (en) | 1999-04-19 | 2000-10-26 | Smithkline Beecham Biologicals Sa | Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
GB0008682D0 (en) | 2000-04-07 | 2000-05-31 | Microbiological Res Authority | Transformation of clostridium difficile |
AU2001261171A1 (en) * | 2000-05-04 | 2001-11-12 | President And Fellows Of Harvard College | Compounds and methods for the treatment and prevention of bacterial infection |
DK1397380T3 (da) * | 2001-06-20 | 2007-05-07 | Univ Ramot | Multipelt antigent peptid, der udviser flere kopier af en epitop af et plaquedannende polypeptid, og fremgangmåder til anvendelse deraf |
US20040029129A1 (en) * | 2001-10-25 | 2004-02-12 | Liangsu Wang | Identification of essential genes in microorganisms |
JP3991280B2 (ja) | 2002-06-05 | 2007-10-17 | 中外製薬株式会社 | 抗体作製方法 |
US7226597B2 (en) * | 2002-06-17 | 2007-06-05 | The Board Of Regents Of The University Of Oklahoma | Mutants of Clostridium difficile toxin B and methods of use |
US20040235139A1 (en) | 2002-12-23 | 2004-11-25 | Demain Arnold L. | Clostridium difficile culture and toxin production methods |
US8084235B2 (en) * | 2003-03-13 | 2011-12-27 | Glaxosmithkline Biologicals S.A. | Purification process for bacterial cytolysin |
US20050020506A1 (en) | 2003-07-25 | 2005-01-27 | Drapeau Susan J. | Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use |
KR101183720B1 (ko) | 2004-01-16 | 2012-09-17 | 다우 글로벌 테크놀로지스 엘엘씨 | 슈도모나스 플루오레센스에서의 포유류 단백질의 발현 |
NZ530709A (en) | 2004-01-21 | 2006-07-28 | Agres Ltd | Improved IGA production method |
CA2553946C (en) * | 2004-02-06 | 2019-02-26 | University Of Massachusetts | Antibodies against clostridium difficile toxins and uses thereof |
GB0421083D0 (en) * | 2004-09-22 | 2004-10-27 | Glaxosmithkline Biolog Sa | Purification process |
US20090087478A1 (en) * | 2004-12-27 | 2009-04-02 | Progenics Pharmaceuticals (Nevada), Inc. | Orally Deliverable and Anti-Toxin Antibodies and Methods for Making and Using Them |
WO2006130925A1 (en) | 2005-06-10 | 2006-12-14 | Monash University | Genetic manipulation of clostridium difficile |
GB0512751D0 (en) | 2005-06-22 | 2005-07-27 | Glaxo Group Ltd | New adjuvant |
EP1987361A4 (en) * | 2006-01-30 | 2009-03-04 | Invitrogen Corp | COMPOSITIONS AND METHODS FOR DETECTING AND QUANTIFYING TOXIC SUBSTANCES IN DISEASE STATES |
PL2004220T3 (pl) * | 2006-03-30 | 2015-11-30 | Zoetis Services Llc | Sposoby i kompozycje do szczepienia drobiu |
WO2007146139A2 (en) * | 2006-06-08 | 2007-12-21 | Cornell Research Foundation, Inc. | Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b |
GB0612301D0 (en) | 2006-06-21 | 2006-08-02 | Morvus Technology Ltd | DNA molecules and methods |
WO2008024769A2 (en) | 2006-08-21 | 2008-02-28 | Raven Biotechnologies, Inc. | Intensified perfusion production method |
US7775167B2 (en) | 2006-08-22 | 2010-08-17 | Monsanto Technology Llc | Custom planter and method of custom planting |
JP2010522135A (ja) | 2006-10-09 | 2010-07-01 | チャールストン ラボラトリーズ,インコーポレイテッド | 医薬組成物 |
US9023352B2 (en) * | 2007-02-20 | 2015-05-05 | Tufts University | Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein |
CN101617362B (zh) * | 2007-03-02 | 2012-07-18 | 松下电器产业株式会社 | 语音解码装置和语音解码方法 |
EP2014760A1 (en) | 2007-06-13 | 2009-01-14 | CMC Biopharmaceuticals A/S | A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process |
US9096638B2 (en) | 2007-09-06 | 2015-08-04 | Geneohm Sciences Canada, Inc. | Detection of toxigenic strains of Clostridium difficile |
RU2550271C2 (ru) * | 2007-09-14 | 2015-05-10 | Санофи Пастер Байолоджикс Ко. | Иммуногенная композиция для лечения или профилактики clostridium difficile, способ ее получения и способ индукции иммунного ответа к c. difficile |
WO2009132082A2 (en) * | 2008-04-22 | 2009-10-29 | Medical College Of Georgia Research Institute, Inc. | Immunogenic compositions containing ceramide and methods of use thereof |
WO2009139919A2 (en) | 2008-05-15 | 2009-11-19 | Tufts University | Methods for diagnosis of clostridium diffcile and methods and vectors for recombinant toxin expression |
US9421251B2 (en) | 2008-06-25 | 2016-08-23 | Novartis Ag | Rapid responses to delayed booster immunisations |
EP2146490A1 (en) | 2008-07-18 | 2010-01-20 | Alcatel, Lucent | User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems |
CA2733425A1 (en) | 2008-08-06 | 2010-02-11 | Emergent Product Development Uk Limited | Vaccines against clostridium difficile and methods of use |
WO2010036826A1 (en) | 2008-09-24 | 2010-04-01 | Sanofi Pasteur Biologics Co. | Methods and compositions for increasing toxin production |
EP2346523A4 (en) | 2008-10-01 | 2014-12-31 | Us Health | MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM |
WO2010037402A1 (en) * | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
KR20110100189A (ko) | 2008-12-03 | 2011-09-09 | 베링거잉겔하임베트메디카게엠베하 | 백신 생산 방법 |
MY160201A (en) | 2008-12-09 | 2017-02-28 | Coley Pharm Group Inc | Immunostimulatory oligonucleotides |
GB0901001D0 (en) * | 2009-01-22 | 2009-03-04 | Univ Nottingham | Methods |
US8709428B2 (en) | 2009-02-20 | 2014-04-29 | Health Protection Agency | Antibodies to Clostridium difficile toxins |
EP2470664A4 (en) * | 2009-08-27 | 2013-01-16 | Synaptic Res Llc | NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS |
US10046040B2 (en) * | 2009-11-16 | 2018-08-14 | University Of Maryland, Baltimore | Multivalent live vector vaccine against Clostridium difficile-associated disease |
CA2782406A1 (en) * | 2009-12-02 | 2011-06-09 | Tufts University | Atoxic recombinant holotoxins of clostridium difficile as immunogens |
GB0921288D0 (en) * | 2009-12-04 | 2010-01-20 | Health Prot Agency | Therapies for preventing or suppressing clostridium difficile infection |
TW201136603A (en) * | 2010-02-09 | 2011-11-01 | Merck Sharp & Amp Dohme Corp | 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition |
CN101870978A (zh) * | 2010-03-23 | 2010-10-27 | 王世霞 | 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗 |
NZ602958A (en) | 2010-03-30 | 2014-07-25 | Pfenex Inc | High level expression of recombinant toxin proteins |
US8765399B2 (en) | 2010-05-18 | 2014-07-01 | Montefiore Medical Center | Cultures and protocols for diagnosis of toxigenic Clostridium difficile |
US9598472B2 (en) | 2010-09-03 | 2017-03-21 | Valneva Austria Gmbh | Isolated polypeptide of the toxin A and toxin B proteins of C. difficile and uses thereof |
GB201016742D0 (en) | 2010-10-05 | 2010-11-17 | Health Prot Agency | Clostridium difficile antigens |
WO2012078313A2 (en) * | 2010-11-12 | 2012-06-14 | Reflexion Pharmaceuticals, Inc. | Gb1 peptidic libraries and compounds, and methods of screening the same |
SG10201602668VA (en) | 2011-04-22 | 2016-05-30 | Wyeth Llc | Compositions relating to a mutant clostridium difficile toxin and methods thereof |
DK3138916T3 (da) | 2011-05-27 | 2019-08-26 | Glaxosmithkline Biologicals Sa | Immunogen sammensætning |
WO2012166991A1 (en) * | 2011-05-31 | 2012-12-06 | The Board Of Regents Of The University Of Texas Systeem | S-nitrosylation of glucosylating toxins and uses therefor |
SG11201402375VA (en) | 2011-12-08 | 2014-10-30 | Novartis Ag | Clostridium difficile toxin-based vaccine |
AR089797A1 (es) | 2012-01-27 | 2014-09-17 | Merck Sharp & Dohme | Vacunas contra clostridum difficile que comprenden toxinas recombinantes |
WO2014045226A1 (en) | 2012-09-19 | 2014-03-27 | Novartis Ag | Clostridium difficile polypeptides as vaccine |
BR122016023101B1 (pt) | 2012-10-21 | 2022-03-22 | Pfizer Inc | Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile |
CN109776676A (zh) | 2012-11-28 | 2019-05-21 | Cnj控股公司 | 针对艰难梭菌的抗体 |
CN104884081A (zh) | 2012-12-05 | 2015-09-02 | 葛兰素史密丝克莱恩生物有限公司 | 免疫原性组合物 |
GB201223342D0 (en) | 2012-12-23 | 2013-02-06 | Glaxosmithkline Biolog Sa | Immunogenic composition |
EP2968508B1 (en) | 2013-03-15 | 2022-04-27 | Sanofi Pasteur Biologics, LLC | Antibodies against clostridium difficile toxins and methods of using the same |
JP2016516721A (ja) | 2013-03-15 | 2016-06-09 | サノフィ パストゥール インコーポレイテッド | トキソイド、組成物および関連方法 |
WO2014165608A1 (en) | 2013-04-02 | 2014-10-09 | Stc. Unm | Antibiotic protocells and related pharmaceutical formulations and methods of treatment |
AU2014277981B2 (en) | 2013-06-14 | 2019-06-20 | Sanofi Pasteur Inc. | Compositions and methods of immunizing against C. difficile |
WO2015061529A1 (en) | 2013-10-23 | 2015-04-30 | The Rockefeller University | Compositions and methods for prophylaxis and therapy of clostridium difficile infection |
US11160855B2 (en) | 2014-01-21 | 2021-11-02 | Pfizer Inc. | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof |
CA3138763A1 (en) | 2015-11-17 | 2017-05-26 | Pfizer, Inc. | Media and fermentation methods for producing polysaccharides in bacterial cell culture |
CN117244049A (zh) | 2016-02-16 | 2023-12-19 | 哈佛学院院长等 | 病原体疫苗及其生产和使用方法 |
CA3056090A1 (en) | 2017-03-15 | 2018-09-20 | Novavax, Inc. | Methods and compositions for inducing immune responses against clostridium difficile |
US10577665B2 (en) | 2017-09-05 | 2020-03-03 | Mcmaster University | Aptamers for clostridium difficile detection |
BR112020005631A2 (pt) | 2017-09-28 | 2020-12-29 | Pfizer Inc. | Composições e métodos para eliciar uma resposta imune contra o clostridium difficile |
JP6704173B2 (ja) | 2019-09-26 | 2020-06-03 | パナソニックIpマネジメント株式会社 | 開閉器及び分電盤 |
-
2012
- 2012-04-20 SG SG10201602668VA patent/SG10201602668VA/en unknown
- 2012-04-20 WO PCT/IB2012/051999 patent/WO2012143902A1/en active Application Filing
- 2012-04-20 ES ES12720966T patent/ES2742823T3/es active Active
- 2012-04-20 CN CN202010510962.7A patent/CN111647059B/zh active Active
- 2012-04-20 MY MYPI2013701986A patent/MY168205A/en unknown
- 2012-04-20 SG SG2013074992A patent/SG194132A1/en unknown
- 2012-04-20 TW TW108114747A patent/TWI701257B/zh active
- 2012-04-20 PL PL12720966T patent/PL2699587T3/pl unknown
- 2012-04-20 EP EP19167276.5A patent/EP3549949B1/en active Active
- 2012-04-20 NZ NZ616035A patent/NZ616035A/en unknown
- 2012-04-20 CA CA2832712A patent/CA2832712C/en active Active
- 2012-04-20 IL IL270779A patent/IL270779B1/en unknown
- 2012-04-20 EP EP12720966.6A patent/EP2699587B1/en active Active
- 2012-04-20 EP EP19151036.1A patent/EP3505531B1/en active Active
- 2012-04-20 TW TW106131031A patent/TWI671313B/zh active
- 2012-04-20 KR KR1020137030696A patent/KR101667837B1/ko active IP Right Grant
- 2012-04-20 BR BR122019017005-3A patent/BR122019017005B1/pt active IP Right Grant
- 2012-04-20 DK DK19167276.5T patent/DK3549949T3/da active
- 2012-04-20 RU RU2013145170/10A patent/RU2592686C2/ru active
- 2012-04-20 AU AU2012245904A patent/AU2012245904B2/en active Active
- 2012-04-20 ES ES19167276T patent/ES2969952T3/es active Active
- 2012-04-20 CN CN201280030656.7A patent/CN103619871B/zh active Active
- 2012-04-20 PT PT191672765T patent/PT3549949T/pt unknown
- 2012-04-20 DK DK12720966.6T patent/DK2699587T3/da active
- 2012-04-20 BR BR112013027229-5A patent/BR112013027229B1/pt active IP Right Grant
- 2012-04-20 CN CN201611125122.9A patent/CN107022532B/zh active Active
- 2012-04-20 MY MYPI2017001631A patent/MY182429A/en unknown
- 2012-04-20 SI SI201232048T patent/SI3505531T1/sl unknown
- 2012-04-20 SI SI201231646T patent/SI2699587T1/sl unknown
- 2012-04-20 HR HRP20231631TT patent/HRP20231631T1/hr unknown
- 2012-04-20 PL PL19167276.5T patent/PL3549949T3/pl unknown
- 2012-04-20 SI SI201232051T patent/SI3549949T1/sl unknown
- 2012-04-20 TW TW109107042A patent/TWI804717B/zh active
- 2012-04-20 PE PE2018000975A patent/PE20181334A1/es unknown
- 2012-04-20 RU RU2015154443A patent/RU2754446C2/ru active
- 2012-04-20 JP JP2014505775A patent/JP5917682B2/ja active Active
- 2012-04-20 PE PE2013002389A patent/PE20141029A1/es active IP Right Grant
- 2012-04-20 TW TW101114168A patent/TWI650329B/zh active
- 2012-04-20 ES ES19151036T patent/ES2968629T3/es active Active
- 2012-04-20 EP EP23207942.6A patent/EP4365196A2/en active Pending
- 2012-04-20 PL PL19151036.1T patent/PL3505531T3/pl unknown
- 2012-04-20 SG SG10201911993UA patent/SG10201911993UA/en unknown
- 2012-04-20 AR ARP120101365A patent/AR086199A1/es active IP Right Grant
- 2012-04-20 HR HRP20240042TT patent/HRP20240042T1/hr unknown
- 2012-04-20 TW TW111129989A patent/TWI815599B/zh active
- 2012-04-20 US US13/451,631 patent/US8481692B2/en not_active Ceased
- 2012-04-20 FI FIEP19167276.5T patent/FI3549949T3/fi active
- 2012-04-20 HU HUE12720966A patent/HUE047085T2/hu unknown
- 2012-04-20 TW TW108101678A patent/TWI686402B/zh active
- 2012-04-20 PT PT12720966T patent/PT2699587T/pt unknown
- 2012-04-20 MX MX2013012344A patent/MX347521B/es active IP Right Grant
- 2012-04-21 SA SA115360698A patent/SA115360698B1/ar unknown
- 2012-04-21 SA SA112330472A patent/SA112330472B1/ar unknown
- 2012-04-21 SA SA115360697A patent/SA115360697B1/ar unknown
-
2013
- 2013-03-22 US US13/848,909 patent/US8557548B2/en not_active Ceased
- 2013-08-19 US US13/970,048 patent/US8900597B2/en not_active Ceased
- 2013-10-17 IL IL228944A patent/IL228944A/en active IP Right Grant
- 2013-10-21 ZA ZA2013/07818A patent/ZA201307818B/en unknown
- 2013-10-24 CO CO13252702A patent/CO6801643A2/es unknown
-
2014
- 2014-10-31 US US14/529,147 patent/US9745354B2/en active Active
-
2015
- 2015-07-10 US US14/796,741 patent/US9187536B1/en not_active Ceased
- 2015-10-14 US US14/883,000 patent/USRE46376E1/en active Active
-
2016
- 2016-01-21 JP JP2016009882A patent/JP6097853B2/ja active Active
- 2016-04-11 IL IL245047A patent/IL245047A0/en active IP Right Grant
- 2016-05-05 AU AU2016202903A patent/AU2016202903B2/en active Active
- 2016-12-01 US US15/366,702 patent/USRE46518E1/en active Active
-
2017
- 2017-02-17 JP JP2017027808A patent/JP6321239B2/ja active Active
- 2017-07-12 US US15/648,092 patent/US10774117B2/en active Active
- 2017-09-07 IL IL254440A patent/IL254440B/en active IP Right Grant
- 2017-09-11 IL IL254418A patent/IL254418B/en active IP Right Grant
- 2017-10-12 JP JP2017198569A patent/JP2018052938A/ja active Pending
- 2017-10-31 IL IL255345A patent/IL255345B/en active IP Right Grant
- 2017-11-13 AU AU2017261465A patent/AU2017261465B2/en active Active
-
2018
- 2018-02-22 AU AU2018201296A patent/AU2018201296A1/en not_active Abandoned
- 2018-04-03 JP JP2018071560A patent/JP6735784B2/ja active Active
- 2018-10-11 JP JP2018192593A patent/JP6892425B2/ja active Active
-
2019
- 2019-03-20 IL IL265510A patent/IL265510B/en active IP Right Grant
- 2019-03-20 US US16/359,267 patent/US10597428B2/en active Active
- 2019-04-18 US US16/388,011 patent/USRE48863E1/en active Active
- 2019-04-18 US US16/387,999 patent/USRE48862E1/en active Active
- 2019-10-11 AU AU2019246878A patent/AU2019246878B2/en active Active
- 2019-12-05 US US16/704,777 patent/US11535652B2/en active Active
-
2020
- 2020-03-11 IL IL273231A patent/IL273231B/en unknown
- 2020-09-08 AU AU2020230248A patent/AU2020230248B2/en active Active
-
2021
- 2021-05-27 JP JP2021088838A patent/JP7097478B2/ja active Active
-
2022
- 2022-06-27 JP JP2022102418A patent/JP2022126822A/ja active Pending
- 2022-12-15 US US18/066,591 patent/US20230391835A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20231631T1 (hr) | Pripravci koji se odnose na mutantni toksin iz bakterije clostridium difficile i odgovarajući postupci | |
HRP20211170T1 (hr) | Pripravci i postupci koji se odnose na mutantni toksin iz bakterije clostridium difficile | |
NZ766918A (en) | Clostridium histolyticum enzymes and methods for the use thereof | |
AR090417A1 (es) | Plantas resistentes al glifosato y metodos asociados | |
WO2011011463A3 (en) | Manipulation of an alternative respiratory pathway in photo-autotrophs | |
MY172423A (en) | Isopropylmalate synthase from nicotiana tabacum and methods and uses thereof | |
MY187542A (en) | Carbohydrate degrading polypeptide and uses thereof | |
WO2010006312A3 (en) | Methods and compositions for producing carbon-based products in microorganisms | |
MY172266A (en) | Threonine synthase from nicotiana tabacum and methods and uses thereof | |
MX2016009149A (es) | Variantes mejoradas de enzimas. | |
DK3000870T3 (en) | FILAMENTOUS FUNGI WITH CHANGED VISCOSITY PHENOTYPE | |
NZ742660A (en) | Variants of chymosin with improved milk-clotting properties | |
RU2011142793A (ru) | Полученная из микроорганизма протеаза усовершенствованного типа, обеспечивающая свертывание молока | |
IN2014DN00094A (hr) | ||
MX365095B (es) | Métodos y composiciones para incrementar la producción de ácido siálico y tratar condiciones de enfermedades relacionadas siálicas. | |
WO2012093149A3 (en) | Novel cell wall deconstruction enzymes and uses thereof | |
NZ601950A (en) | Method for producing pyripyropene | |
JP6413117B2 (ja) | 高効率な異種タンパク質の製造方法 | |
MY170467A (en) | High molecular weight pha-producing microbe and method of producing high molecular weight pha using same | |
NZ706829A (en) | Novel acyltransferase polynucleotides, polypeptides, and methods of use | |
AU2015344324A8 (en) | Endoxylanase mutant, enzyme composition for biomass decomposition, and method for producing sugar solution | |
JP2016086711A5 (hr) | ||
CN104099363A (zh) | 一种BL21(DE3)ΔaroA菌株的构建方法及其应用 | |
JP2015536347A5 (hr) | ||
IN2015DN02044A (hr) |